NEW YORK, Sept. 4, 2014 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that Ivan Bergstein, M.D., Stemline's Chief Executive Officer, will present at the Rodman & Renshaw 16th Annual Global Investment Conference on Tuesday, September 9, 2014 at 11:40 AM ET. The conference will be held at the New York Palace Hotel in New York, NY. A live webcast of the presentation can be viewed on the company's website at www.stemline.com.
About Stemline Therapeutics
Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel oncology therapeutics that target both cancer stem cells (CSCs) and tumor bulk. Stemline is currently developing two clinical stage product candidates, SL-401 and SL-701. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R). A multicenter, open label clinical trial with SL-401 is currently open for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and advanced acute myeloid leukemia (AML). Stemline is also planning SL-401 trials in additional hematologic cancers including several rare IL-3R+ myeloproliferative disorders. Previously, SL-401 demonstrated single agent activity including multiple durable complete responses (CRs), in a Phase 1/2 trial in several indications including BPDCN and relapsed/refractory AML. SL-701 is an enhanced immunotherapy that activates the immune system to attack tumors. A multicenter, open label clinical trial with SL-701 is currently open for adult patients with glioblastoma multiforme (GBM) in first recurrence. Previously, an earlier version of this therapy demonstrated clinical activity, including durable CRs and partial responses (PRs), in Phase 1/2 trials in adults and children with advanced brain cancers. For more information about Stemline Therapeutics, visit www.stemline.com.
Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The factors that could cause our actual results to differ materially are identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.
CONTACT: Investor Relations Stemline Therapeutics, Inc. 750 Lexington Avenue Eleventh Floor New York, NY 10022 Tel: 646-502-2307 Email: firstname.lastname@example.orgSource:Stemline Therapeutics, Inc.